Stocks
Spero Secures Cash Runway to H2 2029 with $105M Financing
Spero Therapeutics has extended its cash runway into the second half of 2029 following a $105 million nondilutive royalty financing. This move,...
#fda approval 5 articles
Stocks
FDA Clears Subcutaneous Leqembi Iqlik for At-Home Use
The FDA has approved Biogen and Eisai's Leqembi Iqlik, a subcutaneous version of their Alzheimer's treatment, for initiation and maintenance dosing, including...
Stocks
Vertex’s Casgevy Approved for Children as Young as Two
Vertex Pharmaceuticals (VRTX) has received US FDA approval for its gene therapy Casgevy, expanding its indication to children as young as two...
Stocks
AbbVie’s Skyrizi Expands Pediatric Indication to Psoriatic Diseases
AbbVie's Skyrizi has received US FDA approval for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This...
Stocks
FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...